Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 1
1988 2
1991 1
1992 5
1993 5
1994 9
1995 1
1996 3
1997 6
1998 4
1999 7
2000 6
2001 7
2002 6
2003 9
2004 9
2005 14
2006 14
2007 12
2008 15
2009 17
2010 15
2011 23
2012 29
2013 27
2014 22
2015 29
2016 21
2017 20
2018 16
2019 23
2020 22
2021 34
2022 33
2023 36
2024 14

Text availability

Article attribute

Article type

Publication date

Search Results

452 results

Results by year

Filters applied: . Clear all
Page 1
Revisiting neoadjuvant therapy in non-small-cell lung cancer.
Saw SPL, Ong BH, Chua KLM, Takano A, Tan DSW. Saw SPL, et al. Lancet Oncol. 2021 Nov;22(11):e501-e516. doi: 10.1016/S1470-2045(21)00383-1. Lancet Oncol. 2021. PMID: 34735819 Review.
Despite the rapidly evolving treatment landscape in advanced non-small-cell lung cancer (NSCLC), developments in neoadjuvant and adjuvant treatments have been nascent by comparison. ...With further standardisation of trial endpoints across studi …
Despite the rapidly evolving treatment landscape in advanced non-small-cell lung cancer (NSCLC), developments in …
Immunotherapy in Lung Cancer: Current Landscape and Future Directions.
Mamdani H, Matosevic S, Khalid AB, Durm G, Jalal SI. Mamdani H, et al. Front Immunol. 2022 Feb 9;13:823618. doi: 10.3389/fimmu.2022.823618. eCollection 2022. Front Immunol. 2022. PMID: 35222404 Free PMC article. Review.
Immune checkpoint inhibitors (ICIs) have shown tremendous benefit in the treatment of non-small cell lung cancer (NSCLC) and are now being used as first-line therapies in metastatic disease, consolidation therapy following chemoradiation …
Immune checkpoint inhibitors (ICIs) have shown tremendous benefit in the treatment of non-small cell lung cancer …
Impact of lymphadenectomy extent on immunotherapy efficacy in postresectional recurred non-small cell lung cancer: a multi-institutional retrospective cohort study.
Deng H, Zhou J, Chen H, Cai X, Zhong R, Li F, Cheng B, Li C, Jia Q, Zhou C, Petersen RH, Rocco G, Brunelli A, Ng CSH, D'Amico TA, Su C, He J, Liang W, Zhu B; AME Thoracic Surgery Collaborative Group. Deng H, et al. Int J Surg. 2024 Jan 1;110(1):238-252. doi: 10.1097/JS9.0000000000000774. Int J Surg. 2024. PMID: 37755384 Free PMC article.
BACKGROUND: Lymph node (LN) dissection is a common procedure for non-small cell lung cancer (NSCLC) to ascertain disease severity and treatment options. ...The prognostic benefit of DLN count less than or equal to 16 was more significant in immunothera …
BACKGROUND: Lymph node (LN) dissection is a common procedure for non-small cell lung cancer (NSCLC) to ascertain …
Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: CheckMate 153.
Waterhouse DM, Garon EB, Chandler J, McCleod M, Hussein M, Jotte R, Horn L, Daniel DB, Keogh G, Creelan B, Einhorn LH, Baker J, Kasbari S, Nikolinakos P, Babu S, Couture F, Leighl NB, Reynolds C, Blumenschein G Jr, Gunuganti V, Li A, Aanur N, Spigel DR. Waterhouse DM, et al. J Clin Oncol. 2020 Nov 20;38(33):3863-3873. doi: 10.1200/JCO.20.00131. Epub 2020 Sep 10. J Clin Oncol. 2020. PMID: 32910710 Free PMC article. Clinical Trial.
PURPOSE: Limited data exist on the optimal duration of immunotherapy, including for non-small-cell lung cancer (NSCLC). We present an exploratory analysis of CheckMate 153, a largely community-based phase IIIb/IV study, to evaluate the impact of …
PURPOSE: Limited data exist on the optimal duration of immunotherapy, including for non-small-cell lung cancer ( …
Adjuvant Immunotherapy in Patients with Early-Stage Non-small Cell Lung Cancer and Future Directions.
Saw SP, Ang MK, Tan DS. Saw SP, et al. Curr Treat Options Oncol. 2022 Dec;23(12):1721-1731. doi: 10.1007/s11864-022-01034-3. Epub 2022 Dec 1. Curr Treat Options Oncol. 2022. PMID: 36451063 Review.
While cisplatin-based adjuvant chemotherapy has been the standard of care for the past two decades, the recent introduction of immunotherapy has heralded an important milestone in the adjuvant landscape of early-stage non-small cell lung …
While cisplatin-based adjuvant chemotherapy has been the standard of care for the past two decades, the recent introduction of immuno …
Adjuvant therapy in non-small cell lung cancer: current and future directions.
Sangha R, Price J, Butts CA. Sangha R, et al. Oncologist. 2010;15(8):862-72. doi: 10.1634/theoncologist.2009-0186. Epub 2010 Aug 3. Oncologist. 2010. PMID: 20682608 Free PMC article. Review.
The cornerstone of treatment for early-stage non-small cell lung cancer (NSCLC) has long been surgical resection. ...Reassuringly, the National Cancer Institute of Canada Cancer Therapeutics Group JBR.10 trial recently reported a continued survi …
The cornerstone of treatment for early-stage non-small cell lung cancer (NSCLC) has long been surgical resection …
Resectable non-small cell lung cancer Adjuvant chemotherapy: slightly longer survival.
[No authors listed] [No authors listed] Prescrire Int. 2016 Dec;25(177):299-301. Prescrire Int. 2016. PMID: 30758927 Review.
About one-quarter of cases of non- small cell lung cancer are diagnosed sufficiently early, i.e. at stages I to lIlA, to envisage surgical resection. ...There is some disagreement concerning stage IB and IIA disease. In practice, clinical trials show t …
About one-quarter of cases of non- small cell lung cancer are diagnosed sufficiently early, i.e. at stages I to …
Systematic review and meta-analysis of immune checkpoint inhibitors as single agent or in combination with chemotherapy in early-stage non-small cell lung cancer: Impact of clinicopathological factors and indirect comparison between treatment strategies.
Nuccio A, Viscardi G, Salomone F, Servetto A, Venanzi FM, Riva ST, Oresti S, Ogliari FR, Viganò M, Bulotta A, Cameron R, Esposito A, Hines J, Bianco R, Reni M, Cascone T, Garassino MC, Torri V, Veronesi G, Cinquini M, Ferrara R. Nuccio A, et al. Eur J Cancer. 2023 Dec;195:113404. doi: 10.1016/j.ejca.2023.113404. Epub 2023 Oct 26. Eur J Cancer. 2023. PMID: 37948842
BACKGROUND: In non-small cell lung cancer (NSCLC), the immune checkpoint inhibitors (ICI) revolution is rapidly moving from metastatic to early-stage, however, the impact of clinicopathological variables and optimal treatment sequencing remain u …
BACKGROUND: In non-small cell lung cancer (NSCLC), the immune checkpoint inhibitors (ICI) revolution is rapidly …
Survivorship in Non-Small Cell Lung Cancer: Challenges Faced and Steps Forward.
Vijayvergia N, Shah PC, Denlinger CS. Vijayvergia N, et al. J Natl Compr Canc Netw. 2015 Sep;13(9):1151-61. doi: 10.6004/jnccn.2015.0140. J Natl Compr Canc Netw. 2015. PMID: 26358799 Free PMC article. Review.
Improvements in curative therapies and the advent of screening have led to increased numbers of non-small cell lung cancer (NSCLC) survivors. Most survivors have undergone invasive treatment (surgery, radiation therapy, and/or chemotherap …
Improvements in curative therapies and the advent of screening have led to increased numbers of non-small cell …
Rapid Arc-SBRT: Non-Invasive Immune Adjuvant for Advanced Stage Non-Small Cell Lung Carcinoma.
Chairmadurai A, Jain SK, Jain A, Prakash H. Chairmadurai A, et al. Anticancer Agents Med Chem. 2022;22(2):202-205. doi: 10.2174/1871520621666210322105641. Anticancer Agents Med Chem. 2022. PMID: 34225640 Review.
In conjunction with radio-chemotherapy, pulmonary resection is recommended for early-stage nonsmall- cell lung carcinoma but not for advanced-stage NSCLC patients having high-grade metastatic lesions. ...In view of this and the immune adjuvant potentia …
In conjunction with radio-chemotherapy, pulmonary resection is recommended for early-stage nonsmall- cell lung carcinoma …
452 results